Advertisement

CLEVELAND, Oct. 11 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of an Enterprise Agreement for three new Phase III oncology studies with an existing client. These multi-center studies will be deployed utilizing the unified DATATRAK eClinical™ platform.

"DATATRAK is pleased to have three new oncology studies running on our unified eClinical platform. With over 1 million new patients diagnosed with cancer each year and less than 5% of them being enrolled in clinical trials, we are excited to participate in trials with innovative compounds that hold the promise of a cure," said Laurence P. Birch, DATATRAK's Chairman and CEO. "Our knowledge of the complex and unique requirements related to oncology trials has been built into DATATRAK eClinical™; these oncology-specific solutions within our unified platform provide our clients with the necessary tools to deliver clinical trials with safety, simplicity and speed."

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE™, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical resea

'/>"/>

SOURCE

Advertisement
Advertisement